Once-every-four-weeks alirocumab meets in Phase III study

Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported data from the first trials assessing once-every-four-weeks doses of alirocumab ( REGN727, SAR236553) to treat hypercholesterolemia. Doses of 300 mg and 150 mg met the primary endpoint of reducing low-density lipoprotein cholesterol (LDL-C) from baseline to 24 weeks vs. placebo in the Phase III ODYSSEY CHOICE I and CHOICE II trials, respectively.

Biweekly dosing of the human mAb targeting proprotein convertase subtilisin/kexin type 9 ( PCSK9) was previously shown to reduce LDL-C in five other Phase III ODYSSEY trials: OPTIONS I and II, COMBO I, HIGH FH, and ALTERNATIVE. ...